Phone: (414) 918-9822    Email: [email protected]

Multicenter prospective registry of infliximab use for childhood uveitis

Multicenter prospective registry of infliximab use for childhood uveitis

by admin | Feb 21, 2016 | Juvenile Idiopathic Arthritis (JIA) |

Principal Investigators: Egla Rabinovich, MD, MPH, Duke University Medical Center and Deborah Levy, MD, Children’s Hospital of New York – Presbyterian

  1. To examine the efficacy of infliximab for the treatment of persistent uveitis in children, utilizing a prospective multi-center registry.
    1. To develop consensus for the administration schema of infliximab for the treatment of chronic uveitis in children through a consensus conference. We will aim for an agreed methotrexate dose and two different initial doses of infliximab. Twelve interested pediatric rheumatology centers will be chosen from current members of Childhood Arthritis and Rheumatology Research Alliance (CARRA) to participate in this registry.
    2. Using the agreed upon standardized methods, to administer infliximab for the treatment of chronic uveitis in children, while prospectively examining standardized ophthalmologic outcomes.
    3. To apply for funding from Centocor and the Arthritis Foundation to extend the registry to 18 months.
  2. To compare the efficacy between two doses of infliximab for the treatment of persistent childhood uveitis.
  3. To collect prospective multi-center data on the side effects of infliximab administration when used for the treatment of chronic uveitis in children.